PAG
MRNA icon

Pinnacle Advisory Group’s Moderna MRNA Stock Holding History

Pinnacle Advisory Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$276K Buy
+2,104
New +$305K 0.01% 213

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Banque Pictet & Cie
Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

Pinnacle Advisory Group's MRNA Position: Q1 2021 in Review

Pinnacle Advisory Group opened a new position in Moderna (MRNA) in Q1 2021: 2,104 shares worth $276K. The stake represents 0.01% of the portfolio and ranks #213 among its holdings.

777 funds tracked by Wall St. Rank hold MRNA as of Q1 2021.

  • Pinnacle Advisory Group held 2,104 shares of Moderna worth $276K as of Q1 2021.
  • Moderna was a new Pinnacle Advisory Group position in Q1 2021.
  • Moderna made up 0.01% of Pinnacle Advisory Group's portfolio in Q1 2021, its #213 holding.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q1 2021.

Based on Pinnacle Advisory Group's 13F filing for Q1 2021, filed 12 May 2021.